KRAS(G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

PURPOSE: KRAS(G12C) is the most common KRAS mutation in primary lung adenocarcinoma (LUAD). Phase I clinical trials have demonstrated encouraging clinical activity of KRAS(G12C) inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Jones, Gregory D., Caso, Raul, Tan, Kay See, Mastrogiacomo, Brooke, Sanchez-Vega, Francisco, Liu, Yuan, Connolly, James G., Murciano-Goroff, Yonina R., Bott, Matthew J., Adusumilli, Prasad S., Molena, Daniela, Rocco, Gaetano, Rusch, Valerie W., Sihag, Smita, Misale, Sandra, Yaeger, Rona, Drilon, Alexander, Arbour, Kathryn C., Riely, Gregory J., Rosen, Neal, Lito, Piro, Zhang, Haiying, Lyden, David C., Rudin, Charles M., Jones, David R., Li, Bob T., Isbell, James M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102372/
https://ncbi.nlm.nih.gov/pubmed/33593884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4772
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados